Key result
Insulin therapy was associated with a higher incidence of major adverse cardiovascular events compared to non-insulin therapy in type 2 diabetes patients following percutaneous coronary intervention, though the difference was not statistically significant (adjusted HR 1.554, 95% CI 0.793-3.045, p=0.199).
Why the study?
Insulin-treated type 2 diabetes mellitus is associated with a higher cardiovascular risk profile, but its impact on MACE following PCI remains unclear.
Does insulin therapy compared to non-insulin therapy increase major adverse cardiovascular events in patients with Type 2 Diabetes Mellitus following percutaneous coronary intervention?
Cohort (n=465)
No
Does insulin therapy compared to non-insulin therapy increase major adverse cardiovascular events in patients with Type 2 Diabetes Mellitus following percutaneous coronary intervention?
In patients with T2DM undergoing PCI, insulin therapy is associated with a numerically higher but not statistically significant risk of 12-month MACE compared to oral hypoglycemic agents, likely reflecting more advanced disease rather than direct harm.
Answers are grounded in this paper and cite their sources.
Associated higher MACE risk with insulin post-PCI was nonsignificant; leaves open confounding by disease severity in T2DM.
BACKGROUND: Insulin-treated type 2 diabetes millatus (ITDM) is associated with heigher cardiovascular risk profile. However its impact on major adverse cardiovascular events (MACE) following poorer percutaneous coronary intervention (PCI) remains unclear. AIMS: This study aimed to evaluate major adverse cardiovascular events in insulin-treated diabetes mellitus (ITDM) and non-insulin-treated diabetes mellitus (Non-ITDM) type 2 diabetes mellitus (T2DM) patients' post-PCI. METHODS: A single-center prospective cohort study was conducted in which 465 T2DM patients undergoing PCI and completing the 1-year follow-up were enrolled. Patients were divided into two groups based on their therapy for DM: ITDM and Non-ITDM. The primary endpoint was MACE, a composite of non-fatal myocardial infarction (MI), stroke, coronary artery bypass grafting (CABG), repeat PCI, and mortality. RESULTS: Logistic regression confirmed higher odds of MACE among ITDM compared to Non-ITDM patients (unadjusted OR = 1.743, 95% CI: 0.865-3.512, p = 0.120; adjusted OR = 1.729, 95% CI: 0.822-3.635, p = 0.149). Kaplan-Meier analysis illustrated increased cumulative incidence of MACE among ITDM over 12 months (Log rank p = 0.113). Similarly, Cox proportional hazards analysis reported higher hazard ratios in the insulin-treated group (unadjusted HR = 1.695, 95% CI: 0.874-3.284, p = 0.118; adjusted HR = 1.554, 95% CI: 0.793-3.045, p = 0.199). Yet the results were not statistically significant. Overall, a higher incidence of MACE was reported among ITDM (12.5%) compared to Non-ITDM (7.5%), particularly repeat PCI (4.8% vs. 2.5%) and stroke (3.8% vs. 1.4%) among T2DM patients after PCI. CONCLUSION: T2DM patients receiving insulin therapy had a higher incidence of adverse cardiovascular events compared to those not on insulin treatment, that insulin-treated patients may represent a higher-risk group for MACE following PCI.
No takes yet. Share an insight, caveat, or question.
Tariq et al. (2026) conducted a cohort in Type 2 Diabetes Mellitus undergoing PCI (n=465). Insulin therapy vs. Non-insulin therapy was evaluated on MACE (composite of non-fatal MI, stroke, CABG, repeat PCI, and mortality) (adjusted HR 1.554, 95% CI 0.793-3.045, p=0.199). Insulin therapy was associated with a higher incidence of major adverse cardiovascular events compared to non-insulin therapy in type 2 diabetes patients following percutaneous coronary intervention, though the difference was not statistically significant (adjusted HR 1.554, 95% CI 0.793-3.045, p=0.199).
Synapse has enriched 10 related papers. Consider them for comparative context: